Table 4.
Pharmacokinetic results
| CRPC | MSS CRC | NSCLC | ||||
|---|---|---|---|---|---|---|
| Navarixin 30 mg + Pembrolizumab 200 mg | Navarixin 100 mg + Pembrolizumab 200 mg | Navarixin 30 mg + Pembrolizumab 200 mg | Navarixin 100 mg + Pembrolizumab 200 mg | Navarixin 30 mg + Pembrolizumab 200 mg | Navarixin 100 mg + Pembrolizumab 200 mg | |
| Cycle 1 day 1 | ||||||
| n | 20 | 20 | 19 | 21 | 12 | 13 |
| AUC0–inf, h∙ng/mL | 376 (43.8)a | 954 (50.8)b | 482 (36.5)c | 1120 (36.0)d | 469 (47.5)e | 1230 (46.3)f |
| AUC0–last, h∙ng/mL | 363 (46.0) | 853 (50.0) | 464 (36.6) | 1070 (46.6) | 427 (46.5) | 1140 (57.8) |
| Cmax, ng/mL | 156 (43.8) | 298 (68.3) | 162 (56.0) | 354 (41.6) | 181 (74.0) | 324 (52.2) |
| tlast, hg | 8.00 (7.83–10.00) | 8.00 (7.37–8.08) | 8.0 (7.27–8.33) | 8.00 (7.12–10.02) | 8.00 (7.83–8.25) | 8.00 (6.00–8.07) |
| Cycle 2 day 1 | ||||||
| n | 18 | 17 | 15 | 18 | 12 | 11 |
| AUC0–inf, h∙ng/mL | 534 (49.1) | 1340 (39.7)h | 584 (24.4)e | 954 (38.9)f | 450 (30.6)e | 1360 (62.4)i |
| AUC0–last, h∙ng/mL | 457 (31.5) | 925 (35.7) | 443 (43.2) | 928 (48.9) | 451 (35.1) | 1080 (57.4) |
| Cmax, ng/mL | 191 (40.8) | 272 (69.1) | 147 (69.0) | 276 (53.8) | 179 (48.9) | 338 (60.8) |
| tlast, hg | 8.01 (6.50–8.70) | 8.00 (5.93–8.17) | 7.93 (6.00–8.17) | 8.00 (7.87–8.13) | 8.00 (7.80–8.08) | 8.00 (6.03–8.08) |
Except where noted, data are geometric mean (% geometric coefficient of variation)
AUC0–inf, area under the concentration-time curve from time 0 through infinity; AUC0–last, area under the concentration-time curve from time 0 through last measurable concentration; Cmax, maximum concentration; CRPC, castration-resistant prostate cancer; MSS CRC, microsatellite-stable colorectal cancer; NSCLC, non–small-cell lung cancer; tlast, time of last measurable concentration
an = 19
bn = 18
cn = 17
dn = 16
en = 10
fn = 9
gData are median (range)
hn = 11
in = 7